MedPath

ROSWELL PARK CANCER INSTITUTE

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers

Not Applicable
Completed
Conditions
Healthy Subject
Cigarette Smoker
Current Smoker
Interventions
Other: Electronic Cigarette
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Questionnaire Administration
First Posted Date
2015-10-15
Last Posted Date
2018-06-12
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
36
Registration Number
NCT02575885
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Phase 1
Withdrawn
Conditions
Colon Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Rectal Adenocarcinoma
Stage III Pancreatic Cancer
Stage IVA Rectal Cancer
Stage IIIA Colon Cancer
Stage IIIB Colon Cancer
Stage IIIC Colon Cancer
Interventions
Other: Laboratory Biomarker Analysis
Drug: pan FGFR Kinase Inhibitor BGJ398
Other: Pharmacological Study
First Posted Date
2015-10-14
Last Posted Date
2016-05-20
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT02575508
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation

Phase 1
Completed
Conditions
Stomatitis
Head and Neck Squamous Cell Carcinoma
Pain
Interventions
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2015-08-25
Last Posted Date
2022-07-25
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
60
Registration Number
NCT02531906
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer

Not Applicable
Completed
Conditions
Head and Neck Carcinoma
Xerostomia
Interventions
Other: Quality-of-Life Assessment
Procedure: Transcutaneous Acupoint Electrical Stimulation
First Posted Date
2015-06-17
Last Posted Date
2022-07-25
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
30
Registration Number
NCT02474095
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2
Active, not recruiting
Conditions
Glioblastoma
Gliosarcoma
Interventions
First Posted Date
2015-05-28
Last Posted Date
2025-03-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
66
Registration Number
NCT02455557
Locations
πŸ‡ΊπŸ‡Έ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Phase 2
Terminated
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma
Radiation-Induced Pneumonitis
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Other: Placebo
Biological: Durvalumab
Procedure: Quality-of-Life Assessment
First Posted Date
2015-05-22
Last Posted Date
2020-04-06
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT02452463
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Phase 1
Terminated
Conditions
Neoplasms, Ovarian
Ovary Neoplasms
Ovarian Cancer
Cancer of Ovary
Cancer of the Ovary
Ovary Cancer
Interventions
First Posted Date
2015-05-04
Last Posted Date
2025-06-19
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
25
Registration Number
NCT02432378
Locations
πŸ‡ΊπŸ‡Έ

UPMC CancerCenter at Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1
Terminated
Conditions
Lymphoma
Solid Neoplasm
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-04-13
Last Posted Date
2022-07-25
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
10
Registration Number
NCT02414724
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase 2
Completed
Conditions
Carcinoid Tumor
Metastatic Carcinoid Tumor
Neuroendocrine Neoplasm
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
First Posted Date
2015-03-26
Last Posted Date
2023-12-26
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
32
Registration Number
NCT02399215
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Rectal Adenocarcinoma
Recurrent Colon Carcinoma
Recurrent Rectal Carcinoma
Stage IVA Rectal Cancer
Stage IVA Colon Cancer
Stage IVB Rectal Cancer
Colon Adenocarcinoma
Stage IVB Colon Cancer
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2015-03-19
Last Posted Date
2021-07-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
42
Registration Number
NCT02393755
Locations
πŸ‡ΊπŸ‡Έ

City of Hope Comprehensive Cancer Center, Duarte, California, United States

πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Β© Copyright 2025. All Rights Reserved by MedPath